Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population

• Status: Active, not recruiting
• Trial end date: 2029-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Cancer Center, Korea
• Collaborators: Chonnam National University Hospital; Chuncheon Sacred Heart Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Incheon St.Mary's Hospital/The Catholic University; International Agency for Research on Cancer; Kangdong Sacred Heart Hospital; Kosin University Gospel Hospital; Kyungpook National University; Kyungpook National University Hospital; Pusan National University Hospital; SMG-SNU Boramae Medical Center; The Catholic University of Korea; Uijeongbu St. Mary's Hospital/The Catholic University
• Treatments: Bismuth

Criteria

Inclusion Criteria:

• Men and women aged 40-65 who are invited to participate in the National Cancer Screening Program and receive upper endoscopy

• Willingness to sign an informed consent form

• Good health, as determined by medical history and physical examination at enrollment

Exclusion Criteria:

• Personal history of gastric cancer

• Family history of gastric cancer in a first degree relative

• Diagnosis and active treatment for other organ cancer except carcinoma in situ within 5 years

• Current treatment for serious medical condition which could hinder participation (such as liver cirrhosis, renal failure, pulmonary dysfunction including COPD or asthma, or uncontrolled infection)

• Inadequate cardiovascular function including (a) New York Heart Association class III or IV heart disease, (b) unstable angina or myocardial infarction history, (c) history of significant ventricular arrhythmia requiring medication with antiarrhythmics, and (d) history of cerebrovascular accident

• Requirement for therapeutic anticoagulant therapy, aspirin

• Gastric resections due to benign disease

• H. pylori eradication therapy history

• Mental incompetence to understand and sign informed consent

• Alcoholism, drug abuse

• Serious chronic diseases according to the evaluation of the study physician

• Presence of a contraindication to the use of eradication treatment regimens

• Inability to provide an informed consent

• Pregnant or lactating women

• Treatment required due to peptic ulcer, gastric cancer or esophageal cancer identified during the endoscopic examination